Acetaminophen (CID 1983) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(53)
 
 
Inactive(897)
 
 
Inconclusive(64)
 
 
Unspecified(1825)
 
 
Top Targets:
p450(39)
 
 
 
 
 
7TM GPCR Srx(27)
 
 
 
7TM GPCR Srsx(17)
 
 
 
NR LBD TR(14)
 
 
GT1 Gtf like(13)
 
 
BioAssay Types:
Confirmatory(513)
 
 
 
 
Literature(437)
 
 
 
 
 
Screening(269)
 
 
 
BioActivity Types:
Potency(419)
 
 
 
 
IC50(155)
 
 
 
 
 
Ki(17)
 
 
 
Kd(3)
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 2505    Data Row: 2839   Total Pages: 57   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103178971]
Ki 4.1Inhibition of human carbonic anhydrase 12 catalytic domain by stopped-flow CO2 hydration assay [AID342484, Type: Literature]Carbonic anhydrase 12 [gi:5915866]
View
2
[SID103178971]
Kd 5.79Binding affinity to human CYP1A1-heme complex [AID536418, Type: Literature]
View
3
[SID103178971]
Ki 6.2Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay [AID331292, Type: Literature]Carbonic anhydrase 2 [gi:115456]
View
4
[SID103178971]
Ki 6.2Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydration assay [AID342476, Type: Literature]Carbonic anhydrase 2 [gi:115456]
View
5
[SID103178971]
Kd 6.64Binding affinity to rat CYP2B1-heme complex [AID536419, Type: Literature]
View
6
[SID103178971]
Ki 7.1Inhibition of human carbonic anhydrase 3 by stopped-flow CO2 hydration assay [AID342477, Type: Literature]Carbonic anhydrase 3 [gi:134047703]
View
7
[SID103178971]
Ki 9.1Inhibition of human carbonic anhydrase 7 by stopped-flow CO2 hydration assay [AID342482, Type: Literature]Carbonic anhydrase 7 [gi:1168744]
View
8
[SID103178971]
Ki 9.23Inhibition of mouse recombinant carbonic anhydrase 15 by stopped-flow CO2 hydrase assay [AID331293, Type: Literature]Carbonic anhydrase 15 [gi:30580362]
View
9
[SID103178971]
Ki 10Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydration assay [AID342475, Type: Literature]Carbonic anhydrase 1 [gi:115449]
View
10
[SID103178971]
Ki 10Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydrase assay [AID331291, Type: Literature]Carbonic anhydrase 1 [gi:115449]
View
11
[SID103178971]
Ki 10.6Inhibition of human carbonic anhydrase 14 by stopped-flow CO2 hydration assay [AID342485, Type: Literature]Carbonic anhydrase 14 [gi:8928036]
View
12
[SID103178971]
Ki 11.4Inhibition of human carbonic anhydrase 4 by stopped-flow CO2 hydration assay [AID342478, Type: Literature]Carbonic anhydrase 4 [gi:115465]
View
13
[SID103178971]
Kd 19.1Binding affinity to human CYP1A1 [AID536416, Type: Literature]Cytochrome P450 1A1 [gi:117139]
View
14
[SID103178971]
IC50 28.38DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) [AID625146, Type: other]Arachidonate 15-lipoxygenase [gi:126397]
View
15
[SID103178971]
Ki 30.3Inhibition of mouse carbonic anhydrase 13 by stopped-flow CO2 hydration assay [AID342486, Type: Literature]Carbonic anhydrase 13 [gi:30580372]
View
16
[SID103178971]
IC50 44Inhibition of FLAP [AID405531, Type: Literature]
View
17
[SID103178971]
IC50 44Inhibition of LPS-stimulated PGE2 production in human whole blood [AID405541, Type: Literature]
View
18
[SID103178971]
 FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase [AID588216, Type: Literature]
View
19
[SID103178971]
 FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase [AID588217, Type: Literature]
View
20
[SID103178971]
 FDA HLAED, liver enzyme composite activity [AID588214, Type: Literature]
View
21
[SID48413133]
 DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results [AID1199, Type: other]
View
22
[SID48413133]
 DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results [AID1205, Type: other]
View
23
[SID48413133]
 DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results [AID1208, Type: other]
View
24
[SID48415047]
 DSSTox (EPAFHM) EPA Fathead Minnow Acute Toxicity [AID1188, Type: other]
View
25
[SID48415502]
 DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
26
[SID56422763]
 Aqueous Solubility from MLSMR Stock Solutions [AID1996, Type: other]
View
27
[SID103178971]
 Drug level in mouse brain at 50 mg/kg, po [AID263727, Type: Literature]
View
28
[SID103178971]
 Hepatotoxicity in CD1 mouse assessed as reduction in hepatic glutathione levels at 6 mmol/kg [AID304904, Type: Literature]
View
29
[SID103178971]
 Hepatotoxicity in CD1 mouse assessed as reduction in renal glutathione levels at 6 mmol/kg [AID304905, Type: Literature]
View
30
[SID103178971]
 Hepatotoxicity in CD1 mouse assessed as increased plasma GPT levels at 6 mmol/kg [AID304907, Type: Literature]
View
31
[SID103178971]
 Hepatotoxicity in CD1 mouse assessed as increased plasma GOT levels at 6 mmol/kg [AID304909, Type: Literature]
View
32
[SID103178971]
 Hepatotoxicity against HEPG2 cells at 100 uM after 6 to 8 hrs by tryptan blue exclusion test [AID304912, Type: Literature]
View
33
[SID103178971]
 Hepatotoxicity against HEPG2 cells at 200 uM after 6 to 8 hrs by tryptan blue exclusion test [AID304913, Type: Literature]
View
34
[SID103178971]
 Hepatotoxicity against human hepatocytes after 6 to 8 hrs by tryptan blue exclusion test [AID304914, Type: Literature]
View
35
[SID103178971]
 Induction of apoptosis in HEPG2 cells at 100 uM after 6 to 8 hrs by Hoechst staining [AID304915, Type: Literature]
View
36
[SID103178971]
 Induction of apoptosis in human hepatocytes after 6 to 8 hrs by Hoechst staining [AID304917, Type: Literature]
View
37
[SID103178971]
 Upregulation of Fas-ligand in HEPG2 cells by western blot [AID304918, Type: Literature]
View
38
[SID103178971]
 Upregulation of Fas-ligand in human hepatocytes by western blot [AID304919, Type: Literature]
View
39
[SID103178971]
 Activation of CAR in HEPG2 cells at 100 uM by western blot [AID304920, Type: Literature]
View
40
[SID103178971]
 Activation of CAR in human hepatocytes by western blot [AID304921, Type: Literature]
View
41
[SID48413133]
 DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results [AID1189, Type: other]
View
42
[SID103178971]
 Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins [AID678713, Type: Literature]Cytochrome P450 2C9 [gi:6686268]
View
43
[SID103178971]
 Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins [AID678713, Type: Literature]Cytochrome P450 2C9 [gi:6686268]
View
44
[SID103178971]
 Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins [AID678713, Type: Literature]Cytochrome P450 2C9 [gi:6686268]
View
45
[SID103178971]
 Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins [AID678716, Type: Literature]Cytochrome P450 3A4 [gi:116241312]
View
46
[SID103178971]
 Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins [AID678716, Type: Literature]Cytochrome P450 3A4 [gi:116241312]
View
47
[SID103178971]
 Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins [AID678716, Type: Literature]Cytochrome P450 3A4 [gi:116241312]
View
48
[SID103178971]
 Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins [AID678717, Type: Literature]Cytochrome P450 3A4 [gi:116241312]
View
49
[SID103178971]
 Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins [AID678717, Type: Literature]Cytochrome P450 3A4 [gi:116241312]
View
50
[SID103178971]
 Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins [AID678717, Type: Literature]Cytochrome P450 3A4 [gi:116241312]
View